Quantitative Investment Management LLC Has $1.80 Million Stock Position in IQVIA Holdings Inc. $IQV

Quantitative Investment Management LLC reduced its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 47.6% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 9,301 shares of the medical research company’s stock after selling 8,444 shares during the period. Quantitative Investment Management LLC’s holdings in IQVIA were worth $1,797,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in IQV. Moore Capital Management LP increased its holdings in shares of IQVIA by 588.6% during the second quarter. Moore Capital Management LP now owns 55,756 shares of the medical research company’s stock worth $10,773,000 after buying an additional 47,659 shares in the last quarter. Sigma Planning Corp acquired a new position in shares of IQVIA in the 2nd quarter worth approximately $350,000. Nichols & Pratt Advisers LLP MA grew its position in IQVIA by 3.0% during the 2nd quarter. Nichols & Pratt Advisers LLP MA now owns 135,620 shares of the medical research company’s stock worth $26,204,000 after acquiring an additional 3,964 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its position in IQVIA by 3.0% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 356,505 shares of the medical research company’s stock worth $68,884,000 after acquiring an additional 10,317 shares during the last quarter. Finally, Wedbush Securities Inc. increased its holdings in IQVIA by 13.7% during the 2nd quarter. Wedbush Securities Inc. now owns 1,342 shares of the medical research company’s stock valued at $259,000 after purchasing an additional 162 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

IQVIA Stock Down 0.2%

NYSE IQV opened at $261.29 on Tuesday. The stock has a market capitalization of $43.01 billion, a P/E ratio of 32.42, a price-to-earnings-growth ratio of 2.24 and a beta of 1.18. IQVIA Holdings Inc. has a 52 week low of $154.50 and a 52 week high of $265.25. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. The stock has a fifty day moving average of $224.00 and a 200-day moving average of $190.15.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.03 by $0.12. The business had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The firm’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities research analysts forecast that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA declared that its board has authorized a share buyback plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s leadership believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of research firms have commented on IQV. Mizuho boosted their price objective on IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Morgan Stanley restated an “equal weight” rating and issued a $200.00 target price (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. Stifel Nicolaus upped their price target on shares of IQVIA from $220.00 to $276.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Wall Street Zen lowered shares of IQVIA from a “buy” rating to a “hold” rating in a report on Saturday. Finally, Barclays restated an “overweight” rating on shares of IQVIA in a research report on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $241.88.

Insider Buying and Selling at IQVIA

In related news, insider W Richard Staub sold 5,500 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the completion of the sale, the insider directly owned 13,312 shares of the company’s stock, valued at $3,097,436.16. The trade was a 29.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Eric Sherbet sold 5,000 shares of the stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the completion of the transaction, the insider owned 20,999 shares in the company, valued at $5,232,110.84. This represents a 19.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 12,913 shares of company stock valued at $3,098,793. 1.70% of the stock is currently owned by company insiders.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.